News
Biologics for JIA? Not So Fast, Say Insurers
MedPage Today
It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.
Arthritis Predicts Hepatic Fibrosis in Hemochromatosis
Mayo Clinic Proceedings reports the results of a retrospective, cross-sectional of patients with HFE hemochromatosis showing that advanced hepatic fibrosis is primarily seen in those with arthritis due to HFE hemochromatosis.
Pre-exposure Prophylaxis for COVID-19 (4.22.22)
Dr. Jack Cush discusses the news and recent journal reports from last weeks RheumNow.com, and answers viewer questions from #ACA - Ask Cush Anything.
COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients
Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD). Survey data from 7005 vaccinated and unvaccinated, adult RMD respondents from 102 countries was analyzed.
Evusheld as Protective Therapy in High Risk COVID-19 Patients
A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19.
TNR - Controversies in PsA
Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.
The PsA Expert panelists included:
Faith in Exercise Benefit Boosts Actual Benefit in SpA
MedPage Today
Patients with axial spondyloarthritis (SpA) got more bang for their exercise buck in a randomized trial when they had good opinions about their workout program, with better persistence with exercise at 1 year relative to a control group, researchers said.
Dietary Improvement in Psoriatic Arthritis
The results of the DIETA trial showed that dietary changes may control psoriatic arthritis (PsA) disease activity, independent of weight loss.
Now Available: TNR - Psoriatic Arthritis Journal Club
A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.
Male vs. Female Responders (4.15.2022)
Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic.
Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor
MedPage Today
Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.
